Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9420347 | 0.87 | KMT2A (0.52) | KMT2AMEN1HPGDALDH1A1ATM | |
| SCHEMBL4864080 | 0.85 | TYMS (0.48) | KMT2AMEN1HPGDALDH1A1MAPT | |
| SCHEMBL4764015 | 0.85 | KMT2A (0.69) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL4770759 | 0.85 | KMT2A (0.55) | KMT2AMEN1HPGDALDH1A1MAPT | |
| SCHEMBL4762572 | 0.83 | ALDH1A1 (0.63) | KMT2AMEN1HPGDALDH1A1MAPT | |
| SCHEMBL4765196 | 0.81 | KMT2A (0.42) | KMT2AMEN1HPGDALDH1A1CYP3A4 | |
| SCHEMBL319866 | 0.80 | KMT2A (0.73) | KMT2AMEN1HPGDALDH1A1CYP3A4 | |
| SCHEMBL5801672 | 0.80 | L3MBTL1 (0.59) | KMT2AMEN1ATMPOLB | |
| SCHEMBL172575 | 0.79 | MAPT (0.44) | KMT2AALDH1A1ATMMAPTSMN1; SMN2 | |
| SCHEMBL1944831 | 0.79 | ALDH1A1 (0.63) | KMT2AMEN1HPGDALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1361873-A4 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1361873-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | KMT2A 3258/4885MEN1 4715/4885HPGD 228/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | KMT2A 2962/4885MEN1 1184/4885HPGD 397/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | KMT2A 2963/4885MEN1 1011/4885HPGD 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.